Insider trading

Period: 120 months Stock: ALEC Plan: Discretionary × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

60 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

60 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

60 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

60 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
60 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
60 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

60 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
4 Sep 2026
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$9.09K 3,625 at 2.51
3.3%
Not planned
3 Sep 2026
Rosenthal Arnon Chief Executive Officer
Sold at will
$193.47K 72,606 at 2.66
3.1%
Not planned
3 Sep 2026
Berkley Neil Lindsay CFO & Chief Business Officer
Sold at will
$77.95K 29,251 at 2.66
7.7%
Not planned
3 Sep 2026
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$13.77K 5,165 at 2.67
4.5%
Not planned
2 Sep 2026
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$1.80K 656 at 2.75
0.6%
Not planned
3 Jun 2026
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$6.54K 3,475 at 1.88
3.5%
Not planned
2 Jun 2026
Rosenthal Arnon Chief Executive Officer
Sold at will
$172.19K 87,216 at 1.97
3.6%
Not planned
2 Jun 2026
Berkley Neil Lindsay CFO & Chief Business Officer
Sold at will
$38.22K 19,360 at 1.97
4.8%
Not planned
2 Jun 2026
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$11.27K 5,709 at 1.97
5.5%
Not planned
2 Mar 2026
Rosenthal Arnon Chief Executive Officer
Sold at will
$173.82K 81,864 at 2.12
3.4%
Not planned
2 Mar 2026
Berkley Neil Lindsay CFO & Chief Business Officer
Sold at will
$62.95K 29,649 at 2.12
7.9%
Not planned
2 Mar 2026
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$17.14K 8,071 at 2.12
6.8%
Not planned
5 Dec 2025
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$5.75K 4,753 at 1.21
3.7%
Not planned
3 Dec 2025
Rosenthal Arnon Chief Executive Officer
Sold at will
$116.83K 104,347 at 1.12
4.1%
Not planned
3 Dec 2025
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$46.67K 41,687 at 1.12
7.7%
Not planned
3 Dec 2025
Berkley Neil Lindsay Chief Bus Ofcr & Interim CFO
Sold at will
$41.72K 37,261 at 1.12
9.1%
Not planned
3 Dec 2025
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$9.02K 8,056 at 1.12
5.9%
Not planned
2 Sep 2025
Rosenthal Arnon Chief Executive Officer
Sold at will
$128.74K 51,562 at 2.50
2.1%
Not planned
2 Sep 2025
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$59.02K 23,638 at 2.50
4.2%
Not planned
2 Sep 2025
Berkley Neil Lindsay Principal Financial Officer
Sold at will
$39.55K 15,842 at 2.50
4.4%
Not planned
2 Sep 2025
Wong-Sarad Grace Principal Accounting Officer
Sold at will
$14.76K 5,910 at 2.50
5.4%
Not planned
2 Jun 2025
Rosenthal Arnon Chief Executive Officer
Sold at will
$69.71K 52,087 at 1.34
2.1%
Not planned
2 Jun 2025
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$31.97K 23,890 at 1.34
4.5%
Not planned
2 Jun 2025
GRASSO MARC Chief Financial Officer
Sold at will
$22.07K 16,488 at 1.34
5.3%
Not planned
3 Mar 2025
Rosenthal Arnon Chief Executive Officer
Sold at will
$59.18K 40,330 at 1.47
1.6%
Not planned
3 Mar 2025
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$42.66K 29,073 at 1.47
5.1%
Not planned
3 Mar 2025
GRASSO MARC Chief Financial Officer
Sold at will
$26.55K 18,091 at 1.47
5.5%
Not planned
3 Mar 2025
Romano Gary Chief Medical Officer
Sold at will
$23.93K 16,306 at 1.47
4.7%
Not planned
2 Dec 2024
Rosenthal Arnon Chief Executive Officer
Sold at will
$131.44K 52,172 at 2.52
2.0%
Not planned
2 Dec 2024
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$66.76K 26,500 at 2.52
4.5%
Not planned
2 Dec 2024
GRASSO MARC Chief Financial Officer
Sold at will
$41.54K 16,489 at 2.52
4.8%
Not planned
2 Dec 2024
Romano Gary Chief Medical Officer
Sold at will
$37.52K 14,892 at 2.52
4.1%
Not planned
3 Sep 2024
Rosenthal Arnon Chief Executive Officer
Sold at will
$129.39K 26,499 at 4.88
1.3%
Not planned
3 Sep 2024
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$67.98K 13,926 at 4.88
4.6%
Not planned
3 Sep 2024
Romano Gary Chief Medical Officer
Sold at will
$41.39K 8,478 at 4.88
4.5%
Not planned
3 Sep 2024
GRASSO MARC Chief Financial Officer
Sold at will
$35.62K 7,297 at 4.88
5.3%
Not planned
22 Aug 2024
Sold at will
$228.39K 44,250 at 5.16
55.8%
Sold half or more
3 Jun 2024
Rosenthal Arnon Chief Executive Officer
Sold at will
$120.62K 25,135 at 4.80
1.3%
Not planned
3 Jun 2024
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$63.37K 13,206 at 4.80
4.1%
Not planned
3 Jun 2024
Romano Gary Chief Medical Officer
Sold at will
$38.58K 8,040 at 4.80
4.1%
Not planned
3 Jun 2024
GRASSO MARC Chief Financial Officer
Sold at will
$33.21K 6,920 at 4.80
4.8%
Not planned
4 Mar 2024
Rosenthal Arnon Chief Executive Officer
Sold at will
$130.39K 18,837 at 6.92
0.9%
Not planned
4 Mar 2024
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$70.39K 10,169 at 6.92
3.1%
Not planned
4 Mar 2024
Romano Gary Chief Medical Officer
Sold at will
$41.55K 6,001 at 6.92
3.0%
Not planned
4 Mar 2024
GRASSO MARC Chief Financial Officer
Sold at will
$39.56K 5,716 at 6.92
3.8%
Not planned
4 Dec 2023
Rosenthal Arnon Chief Executive Officer
Sold at will
$132.50K 23,831 at 5.56
1.2%
Not planned
4 Dec 2023
Kenkare-Mitra Sara President and Head of R&D
Sold at will
$69.61K 12,519 at 5.56
3.7%
Not planned
4 Dec 2023
Romano Gary Chief Medical Officer
Sold at will
$27.99K 5,035 at 5.56
2.4%
Not planned
4 Dec 2023
GRASSO MARC Chief Financial Officer
Sold at will
$25.43K 4,574 at 5.56
2.9%
Not planned
11 Sep 2023
MCGUIRE TERRANCE Director · indirect
Sold at will
$3.00M 500,000 at 6.00
4.4%
Not planned
Showing 1–50 of 60. Page 1 of 2 Older →